Monobenzone
drugOn this page
Also known as BenoquinMonobenzonaNSC-2132P-(benzyloxy)phenolSID11112252albaSID144203947SID144208345SID174006811SID170464724P(BENZYLOXY)PHENOL
Summary
Monobenzone (CHEMBL1388) is an approved small-molecule melanin synthesis inhibitor (ATC D11AX13).
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: D11AX13
- Clinical trials: 1
- Chemistry: 200.23 Da · C13H12O2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1388 |
| Name | Monobenzone |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 7638 |
| ChEBI | CHEBI:34380 |
| ATC | D11AX13 |
| Molecular formula | C13H12O2 |
| Molecular weight | 200.23 |
| InChIKey | VYQNWZOUAUKGHI-UHFFFAOYSA-N |
SMILES: C1=CC=C(C=C1)COC2=CC=C(C=C2)O
IUPAC name: 4-phenylmethoxyphenol
ChEBI definition: The monobenzyl ether of hydroquinone. It is used as a topical drug for medical depigmentation.
Pharmacological roles (ChEBI): melanin synthesis inhibitor, dermatologic drug, allergen.
Also known as: Benoquin, Monobenzona, Monobenzone, NSC-2132, P-(benzyloxy)phenol, SID11112252, MONOBENZONE, alba, SID144203947, SID144208345, SID174006811, SID170464724
Patent coverage: 3,187 distinct patent families (9,068 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Prelamin-A/C, Ferritin light chain, Protein deacetylase HDAC6, Prostaglandin G/H synthase 1, Sodium-dependent noradrenaline transporter, Prostaglandin G/H synthase 2, Sodium-dependent dopamine transporter, Cytochrome P450 1A2, Cytochrome P450 2C19, Hypoxia-inducible factor 1-alpha.
Bioactivity
ChEMBL activities: 16 potent at pChembl ≥ 5 of 17 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| HDAC6 | 6 | IC50 | 988.8 | nM | CHEMBL_ACT_23141044 |
| PTGS1 | 5.99 | IC50 | 1019 | nM | CHEMBL_ACT_7758528 |
| CYP1A2 | 5.8 | AC50 | 1585 | nM | CHEMBL_ACT_6025349 |
| PTGS2 | 5.43 | IC50 | 3726 | nM | CHEMBL_ACT_7758530 |
| SLC6A2 | 5.41 | IC50 | 3886 | nM | CHEMBL_ACT_7756480 |
| SLC6A2 | 5.41 | Ki | 3854 | nM | CHEMBL_ACT_7756481 |
| P12530 | 5.31 | IC50 | 4892 | nM | CHEMBL_ACT_7758598 |
| CYP2C19 | 5.2 | Potency | 6310 | nM | CHEMBL_ACT_4014316 |
| CYP2C19 | 5.2 | AC50 | 6310 | nM | CHEMBL_ACT_6017423 |
| SLC6A2 | 5.16 | AC50 | 6955 | nM | CHEMBL_ACT_25146037 |
| PTGS1 | 5.1 | AC50 | 7876 | nM | CHEMBL_ACT_25206193 |
| SLC6A3 | 5.07 | AC50 | 8556 | nM | CHEMBL_ACT_25124996 |
| LMNA | 5 | Potency | 10000 | nM | CHEMBL_ACT_3645526 |
| HIF1A | 5 | Potency | 10000 | nM | CHEMBL_ACT_4130823 |
| P02791 | 5 | Potency | 10000 | nM | CHEMBL_ACT_4461075 |
| HIF1A | 5 | Potency | 10000 | nM | CHEMBL_ACT_4519100 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
0 indications (0 at ChEMBL trial phase 4).
Clinical trials
Total trials: 1.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05824416 | Not specified | UNKNOWN | Evaluation Of ALBA® Device for Upper Extremity Motor Function In Adults With Subacute And Chronic Acquired Brain Injury |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.